

1 **AI-empowered integrative structural characterization of m⁶A methyltransferase**
2 **complex**

3 Xuhui Yan^{1,3}, Kai Pei^{2,3}, Zeyuan Guan^{1,3}, Feiqing Liu¹, Qiang Wang¹, Junjun Yan¹, Xiaohuan Jin¹,
4 Mengjun Hou¹, Chun Tang^{2,*}, and Ping Yin^{1,*}

5
6 ¹National Key Laboratory of Crop Genetic Improvement, Hubei Hongshan Laboratory, Huazhong
7 Agricultural University, Wuhan 430070, China.

8 ²Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering,
9 PKU-Tsinghua Center for Life Sciences, Center for Quantitative Biology, Peking University, Beijing
10 100871, China.

11
12 *Correspondence:

13 Chun Tang (Tang_Chun@pku.edu.cn) or Ping Yin (yinping@mail.hzau.edu.cn)

14
15 ³These authors contributed equally.
16

17 **Supplementary information**

18

19 **Material and Methods**

20 **Molecular cloning and protein expression**

21 Full-length METTL3, METTL14, WTAP, and VIRMA were amplified from the *Homo sapiens* cDNA
22 library. The truncated genes were subcloned using the standard polymerase chain reaction (PCR)
23 method. All site-directed mutagenesis of WTAP and VIRMA was carried out using the Fusion PCR
24 method.

25

26 For the cryo-EM sample preparation and the methyl transfer assay, the DNAs of human METTL3 and
27 METTL14, WTAP (the WTAP¹⁻²⁷³ for cryo-EM sample preparation; the full-length WTAP for the
28 methyl transfer assay), and VIRMA³⁸¹⁻¹⁴⁸⁶ were subcloned into pFastBac dual. Both METTL14 and
29 WTAP were expressed with an N-terminal His-tag. For the co-expression coupled purification assay,
30 the genes WTAP and VIRMA were subcloned into a modified pFastBac1 vector, fused with a His-tag
31 at the N-terminus. METTL3 and METTL14 were subcloned into pFastBac dual with a Strep-tag and
32 His-tag at N-terminus, respectively. The baculoviruses were generated in Sf9 cells with the bac-to-bac
33 system (Invitrogen). The proteins were co-expressed in Sf9 cells at 27 °C for 60 h before harvesting.

34

35 For the crystallization trials, the WTAP¹³⁰⁻²⁴¹ was subcloned into pET21b (Novagen) and fused with a
36 His-tag at the C-terminus. The plasmid was transformed into BL21 (DE3). One-liter lysogeny broth
37 medium supplemented with 100 mg/mL ampicillin was inoculated with a transformed bacterial pre-

38 culture and shaken at 37 °C until the optical density at 600 nm reached 1.0. After being induced with
39 0.2 mM isopropyl-β-D-thiogalactoside (IPTG) and growing at 16 °C for 14 h before harvesting.

40

41 For the structure-guided mutagenesis analysis, Flag-tag WTAP¹⁻²⁷³ (plasmid 1) and His-tag VIRMA³⁸¹⁻
42 ¹⁴⁸⁶ (plasmid 2) were also subcloned into the pMlink vector with a C-terminal tag, respectively. The
43 Expi293FTM (Invitrogen) cells were cultured in SMM 293TI medium (Sino Biological Inc.) at 37 °C
44 under 5% CO₂ in a ZCZY-CS8 shaker (Shanghai Zhichu Instrument co., Ltd.) and diluted into 2.0 × 10⁶
45 cells/mL for further transfection. For 30 mL cell culture, 30 μg plasmid 1 and 30 μg plasmid 2 were
46 pre-incubated with 180 μg linear polyethylenimines (PEIs) (Polysciences) in 2 mL fresh medium for
47 20 min. The transfection was initiated by adding the mixture to the diluted cell culture. Transfected cells
48 were cultured for 48 h before harvesting.

49

50 **Protein purification**

51 For the cryo-EM sample preparation and mRNA methyltransferase assay, the Sf9 cells were harvested
52 by centrifugation at 2000× g for 15 min and homogenized in ice-cold lysis buffer (25 mM Tris-HCl, pH
53 8.0 and 150 mM NaCl) with 1 mM phenylmethanesulfonyl-fluoride (PMSF). The supernatants were
54 loaded onto Ni-NTA resin (Qiagen) and washed three times with lysis buffer containing 10 mM
55 imidazole. Elution was performed in Elution buffer (25 mM Tris-HCl, 250 mM Imidazole, pH 8.0 and
56 2 mM Dithiothreitol (DTT)), and applied to a Source Q10/100 column (GE Healthcare), followed by a
57 gradient NaCl elution (up to 1 M) in 25 mM Tris-HCl (pH 8.0). Target proteins were further purified
58 on a Superose 6 increase 10/300 GL column (GE Healthcare) equilibrated with SEC buffer (50 mM

59 HEPES, pH 7.5, 50 mM NaCl, and 50 μ M MgCl₂).

60

61 To acquire the METTL3-METTL14-WTAP-VIRMA complex, METTL3-METTL14 protein and
62 WTAP-VIRMA protein were mixed at a molar ratio of 1:0.9 at 4 °C for 30 min. Then the mixture was
63 applied to Superose 6 increase 10/300 column equilibrated with SEC buffer. The METTL3-METTL14-
64 WTAP-VIRMA³⁸¹⁻¹⁴⁸⁶ and the METTL3-METTL14-WTAP-VIRMA were used for the methyl transfer
65 assay. To prepare the sample for the cryo-EM, the peak fractions of METTL3-METTL14-WTAP¹⁻²⁷³-
66 VIRMA³⁸¹⁻¹⁴⁸⁶ were further treated by Gradient fixation (GraFix¹). In detail, low buffer (SEC buffer
67 containing 10% v/v glycerol) was layered on top of an equal volume of freshly prepared high buffer
68 (SEC buffer containing 25% v/v glycerol and 0.05% glutaraldehyde) in a 12.5 mL tube before cooling
69 on ice. Centrifugation was performed at 33,000 rpm in a Beckman SW40Ti swinging bucket rotor for
70 18 h at 4 °C. GraFix peak fractions were collected by gradient fractionator (Biocomp), quenched with
71 100 mM Tris-HCl (pH 8.0), desalted (Hitrap desalting, GE Healthcare) into 25 mM imidazole, pH 8.0,
72 150 mM NaCl, 5 mM DTT and concentrated to 0.4 mg/mL.

73

74 For the crystallization trials, the bacterial pellet was collected and homogenized in a lysis buffer
75 containing 1 mM PMSF. After centrifugation at 14,000 rpm at 4 °C, the supernatant was loaded onto
76 Ni-NTA resin; washed three times with lysis buffer containing 15 mM imidazole, and eluted with
77 Elution buffer. The eluted protein was applied to a Source Q10/100 column. Target proteins were
78 subjected to a Superose 6 10/300 GL column (GE Healthcare), which was equilibrated with a buffer
79 containing 25 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 5 mM DTT.

80 For the co-expression coupled purification assay and structure-guided mutagenesis analysis, the cells
81 were resuspended in 1 mL lysis buffer containing 1 mM PMSF, and lysed by repeated freeze-thaw using
82 liquid nitrogen. After ultracentrifugation, the supernatant was loaded onto a Strep-affinity or Flag-
83 affinity column, washed using lysis buffer, and eluted using a lysis buffer containing 3 mM
84 desthiobiotin, or 0.25 mg/mL Flag peptide (GenScript), respectively. The expression of WTAP and
85 VIRMA were verified by western blot.

86

87 **Crystallization**

88 The WTAP¹³⁰⁻²⁴¹ protein was crystallized by using the hanging-drop vapor diffusion method at 18 °C,
89 and 1 μL of the sample was mixed with an equal volume of reservoir solution. Diamond-shaped crystals
90 appeared overnight from a reservoir solution containing 0.1 M MES (2-(N-morpholino) ethanesulfonic
91 acid), pH 6.0, 160 mM magnesium nitrate, 21 mM sodium bromide, 8% PEG6000 and 11% glycerol.
92 After 48 h of growth, the crystal ceased growing and was flash-frozen in liquid nitrogen. The
93 cryoprotection buffer including 20% v/v ethylene glycol and 10% w/v NDSB-201 added to the reservoir
94 solution. The WTAP¹³⁰⁻²⁴¹ crystal diffracted beyond 2.40 Å at the Shanghai Synchrotron Radiation
95 Facility (SSRF) beamline BL17U1 (ref. 2).

96

97 **Crystal structure determination**

98 The dataset was collected at the SSRF beamline BL17U1 and processed with the HKL3000 (ref. 3).
99 Further processing was performed with the CCP4 suite⁴. Data collection and structural refinement
100 statistics are summarized in Table S1. The structure of the WTAP¹³⁰⁻²⁴¹ was solved by molecular

101 replacement (MR) using the prediction structure from AlphaFold2 (ref. 5) as the search models using
102 the program PHASER⁶. The structure was manually and iteratively refined with PHENIX⁷ and COOT⁸.
103 All figures representing structures were prepared with PyMOL.

104

105 **Sample preparation and cryo-EM data collection**

106 For cryo-EM data acquisition of the METTL3-METTL14-WTAP¹⁻²⁷³-VIRMA³⁸¹⁻¹⁸⁶ complex, right
107 before grid preparation the β -octyl glucoside was added to a final concentration of 0.05%, 3.5 μ L
108 sample were deposited onto a freshly glow-discharged (Thermo Fisher, 20 mA, 120 s) holey carbon
109 grid (Quantifoil R1.2/1.3, Au 300 mesh) and plunged into liquid ethane using an FEI Virobot Mark IV
110 after blotting for 3.5 s with blot force 0, Whatman 597 filter paper at 4 °C and 100 % humidity. Each
111 grid was screened using a Thermo Scientific™ Glacios™ Cryo-EM at 200 keV. Cryo-EM data were
112 collected on a Titan Krios TEM operated at 300 keV and equipped with a K3 Summit direct detector
113 (Gatan) positioned to post a GIF quantum energy filter (slit width 20 eV). Automated data acquisition
114 was carried out using EPU in super-resolution mode at a magnified pixel size of 0.85 Å, with defocus
115 values ranging from -1.0 to -1.5 mm. The total exposure time was set to 2.51 s with 40 frames, resulting
116 in an accumulated dose of about 55.1 e⁻ per Å².

117

118 **Cryo-EM data processing, model building and refinement**

119 The schematic of the data processing pipeline is shown in Fig. S4c. About 915,354 particles from 2040
120 micrographs were automatically picked using the cryoSPARC blob picker⁹. After two-dimensional
121 classification, a total of 890,453 good particles were selected and subjected to several cycles of three-

122 dimensional classification in cryoSPARC⁹. 197,685 particles belonging to the best class were selected;
123 this is followed by nonuniform refinement and local refinement. The METTL3-METTL14-WTAP-
124 VIRMA complex yielded a cryo-EM density with an estimated resolution of 3.10 Å based on gold
125 standard Fourier shell correlation¹⁰.

126

127 The atomic model for the METTL3-METTL14-WTAP-VIRMA complex was built in COOT¹¹ and
128 refined with PHENIX¹². The structure of the METTL3-METTL14-WTAP-VIRMA was validated
129 through the examination of Molprobity¹³ scores and the Ramachandran plots (Table S2).

130

131 **RNA sample preparation and the methyl transfer assay**

132 The specific RNA (5'-UACACUCGAUCUGGACUAAAGCUGCUC-3')¹⁴, and the nonspecific RNA
133 (5'- UACACUCGAUCUUUUUAAAGCUGCUC-3', as negative control) were used in the methyl
134 transfer assay. RNA samples were synthesized using the ABI-3400 Synthesizer with phosphoramidites
135 as previously described¹⁵.

136

137 Reactions were carried out in duplicates with a 10 µL reaction mixture containing [ssRNA]=1 oligos,
138 [SAM]=1 µM, [E]=1 µM in SEC buffer at 25 °C for 20 min. Reactions were terminated by the addition
139 of trifluoroacetic acid (TFA) to a final concentration of 0.1% (v/v) and an 8-µL mixture was transferred
140 to a Half-Area 384-well plate. The activity was measured using an MTase-Glo™ Methyltransferase
141 Assay kit in which the reaction by-product SAH is converted into ATP in a two-step reaction and ATP
142 can be detected through a luciferase reaction¹⁶. The luminescence signal was measured by a TECAN

143 infinite M200 (TECAN).

144

145 ***In vitro* cross-linking**

146 The cross-linking agent bis(sulfosuccinimidyl) suberate (BS3, from Thermo Fisher) was prepared at a
147 concentration of 100 mM in DMSO. BS3 was added to the quaternary protein complex (4.8 μ M) to a
148 final concentration of 1.67 mM. The reaction was performed at 30 °C for 30 min and then quenched by
149 the addition of 20 mM Tris-HCl (pH 7.5). The experiments were triplicated with three parallel samples.

150

151 **Mass spectrometry and data analysis.**

152 The cross-linked protein sample was precipitated with 6 volume pre-chilled acetone at 4 °C and
153 centrifuged for 20 min to remove supernatant. The precipitate sample was dissolved in 8 M urea and
154 0.1 M Tris-HCl (pH 8.5), reduced with 5 mM DTT at 25 °C for 10 min, and alkylated with 10 mM
155 iodoacetamide in dark for 15 min. Subsequently, 3 volumes of Tris-HCl (pH 8.5) were added to dilute
156 the sample, which also contained 1 mM CaCl₂ (to repress Chymotrypsin activity) and 20 mM
157 methylamine (to reduce the modification of the Carbamate modification at the N-terminus of the peptide
158 segment). Trypsin digestion was carried out at 37 °C overnight with sequencing grade modified trypsin
159 (Promega, mass ratio = 1:20). The reaction was quenched with trifluoroacetic acid to a final
160 concentration of 5%.

161

162 Trypsin-digested peptides were purified with C18 Spin Tips (Thermo Fisher Scientific) and were
163 analyzed in the Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific) coupled to an

164 EASY-nLC 1200 liquid chromatography system, with a 75 μm , 2 cm Acclaim PepMapTM 100 column.
165 The peptides were eluted over a 65 min linear gradient from 95% buffer A (water with 0.1% Formic
166 acid) to 35% buffer B (acetonitrile with 0.1% Formic acid) with a flow rate of 200 nL/min. Each full
167 MS scan (Resolution = 70,000) was followed by 15 data-dependent MS2 (Resolution = 17,000), with
168 HCD (higher-energy-collisional-dissociation) and an isolation window of 1.6 m/z. The normalized
169 collision energy was set to 30. Precursors of charge state ≤ 3 were collected for MS2 scans in the
170 enumerative mode; precursors of charge state 3–6 were collected for MS2 scans in cross-link discovery
171 mode. Monoisotopic precursor selection was enabled, and a dynamic exclusion window was set to 30
172 s.

173

174 The cross-linking data were analyzed by pLink2 (ref. 17). The following search parameters were used:
175 MS1 accuracy of ± 20 ppm; MS2 accuracy = ± 20 ppm; enzyme = trypsin (with full tryptic specificity
176 but allowing up to three missed cleavages); crosslinker = BS3 (with an assumed reaction specificity for
177 lysine and protein N termini); fixed modifications = carbamidomethylation on cysteine; variable
178 modifications = oxidation on methionine, hydrolyzed/aminolyzed BS3 from reaction with ammonia or
179 water on a free cross-linker end. The identified candidates have filtered these parameters: false
180 discovery rate (FDR) $< 5\%$, supervised vector machine or SVM score $< 10^{-2}$, and abundance or peptide-
181 spectrum matches (PSMs) ≥ 3 . The experimental cross-links were illustrated with Crosslink-viewer¹⁸.
182 Only cross-links that were observed in at least two biological repeat experiments were used for
183 structural modeling of the quaternary complex.

184

185 **AI-based structure prediction**

186 Each experimental cross-link was converted to distance restraints. They were applied to the C α atoms
187 of the cross-linked residues with an upper distance bound of 26 Å (a 2-Å padding was added to account
188 for local flexibility¹⁹). However, due to the limited reactivity of BS3, multiple binding modes between
189 proteins have to be invoked to account for the intermolecular cross-linking data^{20,21}. On the other hand,
190 due to the sparsity of the restraints, each binding mode cannot be effectively validated.


191

192 We used AlphaFold2 (version 2.2) multimer⁵ to build the structural models of the complex. To narrow
193 the search space, only the structural models of binary complexes were predicted. Prediction of the binary
194 complex was further sped up by including only the N terminal domains of METTL3 (with WTAP) and
195 METTL14 (with VIRMA), to which the majority of the intermolecular cross-links were identified. On
196 the other hand, VIRMA residues D342-D1292 and WTAP residues T148-D237 were included in
197 AlphaFold2 multimer prediction. The initial model of the quaternary complex was further constructed
198 with the incorporation of the known binary complex structures of METTL3-METTL14 catalytic domain
199 and METTL3 ZFD^{15,22} and VIRMA-WTAP (this study).

200

201 The position of the METTL3-METTL14 catalytic domain was further optimized by incorporating the
202 cross-link restraints to residue K398 near the C-terminus of METTL14. Since AlphaFold2 gave a low-
203 confidence prediction to the flexible linker residues²³, database potential²⁴ and a weak radius of gyration
204 potential²⁵ were further incorporated for conformation optimization and packing against the structured
205 portions.



206



207


208 **Fig. S1 The interaction relationship between the subunits of M-M-W-V complex.** Co-express Strep-
 209 METTL3/His-METTL14, Strep-METTL3/His-METTL14/His-WTAP, strep-METTL3/His-
 210 METTL14/His-VIRMA and Strep-METTL3/His-METTL14/His-WTAP/His-VIRMA coupled Strep-
 211 tag purification. Red arrow indicates the WTAP.

212

a**b**

213

214 **Fig. S2 Relative methyl transfer activity of the METTL3-METTL14, METTL3-METTL14-**215 **WTAP-VIRMA³⁸¹⁻¹⁴⁸⁶ and METTL3-METTL14-W-V³⁸¹⁻¹⁴⁸⁶ and METTL3-METTL14-W-V**216 **complexes. a** SDS-PAGE of217 **the METTL3-METTL14, METTL3-METTL14-W-V³⁸¹⁻¹⁴⁸⁶ and METTL3-METTL14-W-V**218 **complexes. b** The methyl transfer activity of MTCs, corresponding to **a**. [ssRNA]= 1 μ M oligos,219 [SAM]=1 μ M, [E]=1 μ M. The error bars represent the SD of three independent measurements.



220

221


222

223

224

Fig. S3 The interactions between WTAP_A and WTAP_B. **a** In the crystal structure, two molecules of WTAP forms a symmetric parallel alpha-helical coiled-coil with hydrophobic interactions. **b** VIRMA-bound WTAP forms an asymmetric coiled-coil with hydrophobic interactions and hydrogen bonds. **c** Sequence alignment of WTAP in *Homo sapiens*, *Danio rerio*, *Drosophila melanogaster* and

225 *Arabidopsis thaliana*. The alignment was generated using the MultAlin and ENDscript programs.
226 Secondary structural elements are shown above. The residues involving in WTAP-VIRMA interaction
227 were illustrated by solid squares.
228



229

230

231

232

233

234


235

236

237


238

Fig. S4 Sample preparation for cryo-EM experiments and the data processing of the METTL3-METTL14-WTAP¹⁻²⁷³-VIRMA³⁸¹⁻¹⁴⁸⁶ complex. **a** Representative SDS-PAGE showing fractions taken across glycerol gradient prepared without/with cross-linking agent glutaraldehyde. Fractions 9 and 10 were pooled for cryo-EM grid preparation. **b** Representative cryo-EM micrograph. **c** Flowchart for cryo-EM data processing of the human METTL3-METTL14-WTAP¹⁻²⁷³-VIRMA³⁸¹⁻¹⁴⁸⁶ complex. The FSC curves of the final refined models of the METTL3-METTL14-WTAP¹⁻²⁷³-VIRMA³⁸¹⁻¹⁴⁸⁶ complex. Local resolutions are color-coded for the METTL3-METTL14-WTAP¹⁻²⁷³-VIRMA³⁸¹⁻¹⁴⁸⁶ complex. The highest resolution of the EM maps reaches 2.80 Å.



239
240
241
242
243
244


Fig. S5 The electron microscopy maps for the METTL3-METTL14-WTAP¹⁻²⁷³-VIRMA³⁸¹⁻¹⁴⁸⁶ complex. a The electron microscopy maps for WTAP_A and WTAP_B. **b** The electron microscopy maps for ARMLs. **c** High and low threshold of METTL3-METTL14-WTAP¹⁻²⁷³-VIRMA³⁸¹⁻¹⁴⁸⁶ complex. Arrow indicates the extra density.




245
 246
 247
 248
 249
 250
 251
 252
 253
 254

Fig. S6 Characterization of the structure of ARMLs. **a** The topological diagram of the ARMLs. VIRMA³⁸¹⁻¹²⁹² is mainly composed of alpha-helices, including 17 ARMLs. Each alpha-helix is ~12 amino-acid long, consisting of two long helices which are 26 and 29 amino-acid, respectively. ARML contains two or three helices, H1 (gray), H2 (orange), and H3 (yellow). ARML 2-4, 6, 7, 9, 12, 15 and 17 consists of three helices while the rest are two-helix units. Two long helices in between of ARML 4-5 and ARML 7-8 mediate the turning of the VIRMA alpha-solenoid. **b** Overall structure of the VIRMA³⁸¹⁻¹²⁹² is represented as cartoon cylindrical helices, with the ARML repeats labeled ARML1 to 17.

a



b



255

256

257


258

259

260

261


Fig. S7 Sequence and structure alignment of the seventeen ARMLs of VIRMA. **a** Sequence alignment of the seventeen ARMLs of VIRMA. Conserved residues that define the ARML consensus motif are highlighted in red and green. **b** Superposition of the VIRMA's ARMLs and the β -Catenin's ARM 2 (wheat, PDB 1BK6). Residues forming H1, H2, and H3 helices of each ARML are highlighted in gray, orange, and yellow, respectively.



263

264 **Fig. S8 Structure-guided mutagenesis analysis of WTAP-VIRMA interaction interfaces.**
 265 Schematic representation of interaction networks between WTAP and VIRMA. Residues in WTAP_A,
 266 WTAP_B, and VIRMA involved in the interactions are shown in cyan, yellow orange and light blue
 267 rectangles, respectively. **b** The density fitting of the inter-subunit interaction interfaces between WTAPs
 268 and VIRMA. **c, d** Co-express WTAP¹⁻²⁷³ muts-Flag/VIRMA³⁸¹⁻¹⁴⁸⁶-His (**c**) and WTAP¹⁻²⁷³-
 269 Flag/VIRMA³⁸¹⁻¹⁴⁸⁶ muts-His (**d**) coupled Flag-tag purification. Residues critical for complex formation
 270 are colored in red.

271



272
 273
 274
 275
 276
 277
 278
 279
 280

Fig. S9 CXMS analysis of METTL3-METTL14-WTAP-VIRMA³⁸¹⁻¹⁴⁸⁶ complex architecture. a Inter-subunit crosslinks MTC, METTL3, METTL14, WTAP and VIRMA³⁸¹⁻¹⁴⁸⁶. The numbers of the corresponding spectra of each cross-link were indicated by the color of the line. Cross-links were filtered by requiring FDR < 0.05 at the spectra level, SVM-value < 1×10^{-2} and spectral counts ≥ 3 . **b** The inter-subunit BS3-crosslinked residue pairs. Residues in METTL3, METTL14, WTAP_A, WTAP_B and VIRMA involved in the crosslinked pairs are shown in magenta, chartreuse, cyan, yellow and light blue rectangles, respectively.

281 **Table S1** Statistics of crystal data collection and refinement of the human WTAP.

282

	WTAP ¹³⁰⁻²⁴¹ PDB: 7YFJ
Space group	<i>P6₁22</i>
Cell dimensions	
a, b, c (Å)	62.75, 62.75, 336.35
α , β , γ (°)	90, 90, 120
Number of molecules in ASU	2
Wavelength (Å)	0.97915
Resolution (Å)	45~2.40(2.49~2.40)
<i>R</i> _{merge} (%)	9.9(97.8)
<i>R</i> _{pim} (%)	3.1(30.0)
<i>I</i> / σ <i>I</i> σ	18.8(2.4)
Completeness (%)	99.5(99.6)
Number of measured reflections	331,188
Number of unique reflections	16,547
Redundancy	20.0(20.7)
Wilson B factor (Å ²)	55.66
<i>R</i> _{work} / <i>R</i> _{free} (%)	21.95/23.98
Number of atoms	1656
Protein	1558
Main chain	756
Side chain	802
Water	84
Other entities	14
Average B value (Å ²)	65.2
Protein	65.3
main chain	87.7
side chain	80.6
Water	86.4
Other entities	132.6
R.m.s. deviations	
Bond lengths (Å)	0.008
Bond angle (°)	0.925
Ramachandran plot statistics (%)	
Most favorable	98.3
Allowed	1.7
Disallowed	0

283 **Table S2** Statistics of cryo-EM data collection and refinement of the METTL3-METTL14-WTAP-
 284 VIRMA complex.
 285

METTL3-METTL14-WTAP ¹⁻²⁷³ -VIRMA ³⁸¹⁻¹⁴⁸⁶	
PDB: 7YG4	
EMBD: EMD-33807	
Data collection and processing	
Microscope	Krios
Voltage (kV)	300
Camera	Gatan K3
Magnification	105,000
Pixel size at detector (Å/pixel)	0.85
Total electron exposure (e ⁻ /Å ²)	55.1
Frames collected during exposure (no.)	40
Defocus range (µm)	-1.0~-1.5
Automation software	EPU
Micrographs collected (no.)	2,040
Micrographs used (no.)	2,027
Total extract particles (no.)	915,354
For each reconstruction	
Refined particles (no.)	197,685
Final particles (no.)	197,685
Point group	C1
Resolution (global, Å)	
FSC 0.5 (unmasked/masked)	5.9/3.6
FSC 0.143 (unmasked/masked)	3.7/3.0
Resolution range (local, Å)	
Map sharpening B factor (Å ²)	96.7
Map sharpening methods	Half-maps correlation
Model composition	
Protein	953
Ligands/DNA/RNA	0
Model refinement	
Refinement package	PHENIX

- real or reciprocal space	Real Space
- resolution cutoff	3.1
Model-Map scores	
- CC	0.85
B factors (\AA^2)	
Protein residues	75.34
Ligands/DNA/RNA	0
R.m.s. deviations from ideal values	
Bonds length (\AA)	0.003
Bond angles ($^\circ$)	0.584

Validation

MolProbity score	1.60
CaBLAM outliers	1.64
Clashscore	7.09
Poor rotamers (%)	0
C-beta deviations	0
EMRinger score (if better than 4 \AA resolution)	1.84
Ramachandran Plot	
Favored (%)	96.68
Outliers (%)	0

286

287

288 **References**

- 289 1 Kastner B, Fischer N, Golas MM et al. GraFix: sample preparation for single-particle electron
290 cryomicroscopy. *Nat Methods*. **5**, 53-55 (2008).
- 291 2 Wang Z, Pan Q, Yang L et al. Automatic crystal centring procedure at the SSRF macromolecular
292 crystallography beamline. *J Synchrotron Radiat*. **23**, 1323-1332 (2016).
- 293 3 Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. *Methods*
294 *Enzymol*. **276**, 307-326 (1997).
- 295 4 Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein
296 crystallography. *Acta Crystallogr D Biol Crystallogr*. **50**, 760-763 (1994).
- 297 5 Evans R, O'Neill M, Pritzel A et al. Protein complex prediction with AlphaFold-Multimer. *bioRxiv*.
298 DOI: <https://doi.org/10.1101/2021.10.04.463034>
- 299 6 McCoy AJ et al. Phaser crystallographic software. *J Appl Crystallogr*. **40**, 658-674 (2007).
- 300 7 Adams PD, Grosse-Kunstleve RW, Hung LW et al. PHENIX: building new software for automated
301 crystallographic structure determination. *Acta Crystallogr D Biol Crystallogr*. **58**, 1948-1954 (2002).
- 302 8 Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol*
303 *Crystallogr*. **60**, 2126-2132 (2004).
- 304 9 Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. cryoSPARC: algorithms for rapid unsupervised
305 cryo-EM structure determination. *Nat Methods*. **14**, 290-296 (2017).
- 306 10 Rosenthal PB, Henderson R. Optimal determination of particle orientation, absolute hand, and
307 contrast loss in single-particle electron cryomicroscopy. *J Mol Biol*. **333**, 721-745 (2003).
- 308 11 Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. *Acta Crystallogr*
309 *D Biol Crystallogr*. **66**, 486-501 (2010).
- 310 12 Adams PD, Afonine PV, Bunkoczi G et al. PHENIX: a comprehensive Python-based system for
311 macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr*. **66**, 213-221 (2010).
- 312 13 Davis IW, Leaver-Fay A, Chen VB et al. MolProbity: all-atom contacts and structure validation for
313 proteins and nucleic acids. *Nucleic Acids Res*. **35**, W375-W383 (2007).
- 314 14 Liu J, Yue Y, Han D et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N-
315 6-adenosine methylation. *Nat Chem Biol*. **10**(2), 93-95(2014).
- 316 15 Huang J, Dong X, Gong Z et al. Solution structure of the RNA recognition domain of METTL3-
317 METTL14 N(6)-methyladenosine methyltransferase. *Protein Cell*. **10**(4), 272-284 (2018).
- 318 16 Hsiao K, Zegzouti H, Goueli SA. Methyltransferase-Glo: a universal, bioluminescent and
319 homogenous assay for monitoring all classes of methyltransferases. *Epigenomics*. **8**, 321-339 (2016).
- 320 17 Chen Z-L, Meng J-M, Cao Y et al. A high-speed search engine pLink 2 with systematic evaluation
321 for proteome-scale identification of cross-linked peptides. *Nature Commun*. **10**(1), 3404 (2019).
- 322 18 Graham M, Combe C, Kolbowski L, Rappsilber J. xiView: A common platform for the downstream
323 analysis of Crosslinking Mass Spectrometry data. *bioRxiv*.

- 324 DOI: <https://doi.org/10.1101/561829>
- 325 19 Czaplewski C et al. Recent developments in data-assisted modeling of flexible proteins. *Front Mol*
326 *Biosci.* **8**, 765562 (2021).
- 327 20 Wang J-H, Gong Z, Dong X et al. Preferential cross-linking of the stereospecific complex over the
328 encounter complexes by DOPA2, a faster cross-linker than DSS. *bioRxiv*.
- 329 DOI: <https://doi.org/10.1101/2022.06.06.494913>
- 330 21 Gong Z, Ding Y-H, Dong X et al. visualizing the ensemble structures of protein complexes using
331 chemical cross-linking coupled with mass spectrometry. *Biophys Rep.* **1**, 127-138 (2015).
- 332 22 Wang X, Feng J, Xue Y et al. Structural basis of N(6)-adenosine methylation by the METTL3-
333 METTL14 complex. *Nature.* **534**, 575-578 (2016).
- 334 23 Tunyasuvunakool K, Adler J, Wu Z et al. Highly accurate protein structure prediction for the human
335 proteome. *Nature.* **596**, 590-596 (2021).
- 336 24 Bermejo GA, Clore GM, Schwieters CD. Smooth statistical torsion angle potential derived from a
337 large conformational database via adaptive kernel density estimation improves the quality of NMR
338 protein structures. *Protein Sci.* **21**, 1824-1836 (2012).
- 339 25 Schwieters CD, Clore GM. A pseudopotential for improving the packing of ellipsoidal protein
340 structures determined from NMR data. *J Phys Chem B.* **112**, 6070-6073 (2008).